Back
 JCT  Vol.3 No.6 A , November 2012
A Phase II Trial of Preoperative Chemoradiotherapy with Oral DPD-Inhibitory Fluoropyrimidines in Patients with Advanced Rectal Cancer
Abstract: Background: Preoperative chemoradiotherapy (CRT) with 5-FU has been widely used to improve local control of disease and to preserve anal sphincter in the treatment of rectal cancer. UFT and S-1 as oral dihydropyrimidine dehydrogenase (DPD)-inhibitory fluoropyrimidines enhance the therapeutic effect of 5-FU by modulating its metabolic pathways. The purpose of this study was to evaluate the efficacy and toxicity of CRT using UFT versus S-1 in patients with locally advanced rectal cancer. Methods: Fifty-nine patients who received preoperative CRT (40 Gy radiotherapy) were randomly assigned to either UFT or S-1 groups. UFT and S-1 were administered during the radiotherapy course. Response to CRT was determined using a histopathologic examination and RECIST of surgically resected specimens and classified as responders (CR, PR and grade 2, 3) or nonresponders (SD, PD and grade 0, 1). Results: All patients were randomly allocated to S-1 group (n = 30) or UFT group (n = 29). Pathological response rate (Grade2 and Grade3) was 57% in the S-1 group and 45% in the UFT group (p = 0.36). Pathological complete response (CR) rate (Grade3) was 7% in the S-1 group and 4% in the UFT group (p = 0.98). There was no statistically significant difference between the two groups in regard to the response rate of RECIST (p = 0.52). There was no statistically significant difference between the groups based on the downstaging rate, resection of tumor, sphincter preservation and marginal invasion. The incidence of Grade 3 diarrhea was significantly more frequent in the S-1 group (7%) compared with the UFT group (0%) (p = 0.02). Conclusion: The results supported the conclusion that CRT using UFT or S-1 is effective and feasible for patients with locally advanced rectal cancer.
Cite this paper: M. Hotchi, H. Okitsu, M. Miura, M. Hamada, Y. Sonaka, Y. Fukuda, T. Ando and S. Kuratate, "A Phase II Trial of Preoperative Chemoradiotherapy with Oral DPD-Inhibitory Fluoropyrimidines in Patients with Advanced Rectal Cancer," Journal of Cancer Therapy, Vol. 3 No. 6, 2012, pp. 989-995. doi: 10.4236/jct.2012.326127.
References

[1]   C. Camma, M. Giunta, F. Fiorica, L. Pagliaro, A. Craxi and M. Cottone, “Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-Analysis,” Journal of the American Medical Association, Vol. 284, No. 8, 2000, pp. 1008-1015. doi:10.1001/jama.284.8.1008

[2]   Colorectal Cancer Collaborative Group, “Adjuvant Radiotherapy for Rectal Cancer: A Systematic Overview of 8,507 Patients from 22 Randomised Trials,” Lancet, Vol. 358, No. 9290, 2001, pp. 1291-1304. doi:10.1016/S0140-6736(01)06409-1

[3]   J. F. Bosset, L. Collette, G. Calais, L. Mineur, P. Maingon, L. Radosevic-Jelic, A. Daban, E. Bardet, A. Beny and J. C. Ollier, EORTC Radiotherapy Group Trial 22921, “Chemotherapy with Preoperative Radiotherapy in Rectal Cancer,” The New England Journal of Medicine, Vol. 355, 2006, pp. 1114-1123. doi:10.1056/NEJMoa060829

[4]   S. Fujii, S. Kitano, K. Ikenaka and T. Shirasaka, “Effect of coadministration of Uracil Or Cytosine on the Anti-Tumor Activity of Clinical Doses of 1-(2-Tetrahy-drofuryl)-5-Fluorouraciland Level of 5-Fluorouracil in Rodents,” Japanese Journal of Cancer Research: Gann, Vol. 70, No. 2, 1979, pp. 209-214.

[5]   T. Shirasaka, Y. Shimamato, H. Ohshimo, M. Yamaguchi, T. Kato, K. Yonekura and M. Fukushima, “Development of A Novel Form of an Oral 5-Fluorouracil Derivative (S-1) Directed to the Potentiation of the Tumor Selective Cytotoxicity of 5-Fluorouracil by Two Biochemical Modulators,” Anti-Cancer Drugs, Vol. 7, No. 5, 1996, pp. 548-557. doi:10.1097/00001813-199607000-00010

[6]   T. Shirasaka, K. Nakano, T. Takechi, H. Satake, J. Uchida, A. Fujioka, H. Saito, H. Okabe, K. Oyama, S. Takeda, N. Unemi and M. Fukushima, “Antitumor Activity of 1 M Tegafur-0.4 M 5-Chloro-2,4-Dihydroxypyridine-1 M Potassium Oxonate (S-1) Against Human Colon Carcinoma Orthotopically Implanted into Nude Rats,” Cancer Research, Vol. 56, No. 11, 1996, pp. 2602-2606.

[7]   P. M. Hoff, N. Janjan, E. D. Saad, J. Skibber, C. Crane, Y. Lassere, K. R. Cleary, S. Benner, J. Randolph, J. L. Abbruzzese and R. Pazdur, “Phase I Study of Preoperative Oral Uracil and Tegafur plus Leucovorin and Radiation Therapy in Rectal Cancer,” Journal of Clinical Oncology, Vol. 18, No. 20, 2000, pp. 3529-3534.

[8]   J. Feliu, J. Calvilio, A. Escribano, J. de Castro, M. E. Sanchez, A. Mata, E. Espinosa, A. G. Grande, A. Mateo, M. G. Baron, “Neoadjuvant Therapy of Rectal Carcinoma with Uft-Leucovorin plus Radiotherapy,” Annals of Oncology, Vol. 13, No. 5, 2002, pp. 730-736. doi:10.1093/annonc/mdf116

[9]   L. W. Vestermark, A. Jacobsen, C. Qvortrup, F. Hansen C. Bisgaard, G. Baatrup, P. Rasmussen and P. Pfeiffer, “Long-Term Results of a Phase II Trial of High Dose Radiotherapy (60 Gy) and UFT/l-Leucovorin in Patients with Non-Resectable Locally Advanced Rectal Cancer (LARC),” Acta Oncologica, Vol. 47, No. 3, 2008, pp. 428-433. doi:10.1080/02841860701798866

[10]   C. Fernández-Martos, J. Aparicio, C. Bosch, M. Torregrosa, J. M. Campos, S. Garcera, J. M. Vicent, I. Maestu, M. A. Climent, J. L. Mengual, A. Tormo, A. Hernandez, R. Estevan J. M. Richart, V. Viciano, N. Uribe, J. Campos, R. Puchades F. Arlandis and D. Almenar, “Preoperative Uracil, Tegafur, and Concomitant Radiotherapy in Operable Rectal Cancer: A Phase II Multicenter Study with 3 Years’ Follow-Up,” Journal of Clinical Oncology, Vol. 22, 15, 2004, pp. 3016-3022. doi:10.1200/JCO.2004.11.124

[11]   A. de la Torre, M. I. García-Berrocal, F. Arias, I. Zapata, C. de la Fuente, E. Fernandez-Lizarbe, G. Vergara, B. Belinchon, M. Veiras, R. Moleron and I. Millan, “Preoperative Chemoradiotherapy for Rectal Cancer: Randomized Trial Comparing Oral Uracil and Tegafur and Oral Leucovorin vs. Intravenous 5-Fluorouracil and Leucovorin,” International Journal of Radiation Oncology, Biology, Physics, Vol. 70, No. 1, 2008, pp. 102-110. doi:10.1016/j.ijrobp.2007.05.068

[12]   M. Fukushima, K. Sakamoto, M. Sakata, F. Nakagawa, H. Saito and Y. Sakata, “Gimeracil, a Component of S-1, May Enhance the Antitumor Activity of X-Ray Irradiation in Human Cancer Xenograft Models in Vivo,” Oncology Reports, Vol. 24, No. 5, 2010, pp. 1307-1313. doi:10.3892/or_00000987

[13]   S. Morimoto, M. Shimada, N. Kurita, H. Sato, T. Iwata, M. Nishioka, K. Yoshikawa, T. Miyatani, H. Kashihara, C. Takasu and H. Ikushima, “Preoperative Radiotherapy Combined with S-1 for Advanced Lower Rectal Cancer: Phase I Trial,” Hepatogastroenterology, Vol. 59, No. 117, 2012, pp. 1428-1432. doi:10.5754/hge11699

[14]   “Response Assessment of Nonsurgical Treatment for Colorectal Carcinoma. Japanese Classification of Colorectal Carcinoma. Japanese Society for Cancer of the Colon and Rectum, “1st English Edition, Kanehara & Co. Ltd., Tokyo, 1997, pp. 77-82.

[15]   R. Glynne-Jones, J. Dunst and D. Sebag-Montefiore, “The Integration of Oral Capecitabine into Chemoradiation Regimens for Locally Advanced Rectal Cancer: How Successful Have We Been?” Annals of Oncology, Vol. 17, 3, 2006, pp. 361-371. doi:10.1093/annonc/mdj052

[16]   N. A. Janjan, J. Abbruzzese, R. Pazdur, V. S. Khoo, K. Cleary, R. Dubrow, J. Ajani, T. A. Rich, M. S. Goswitz, P. A. Evetts, P. K. Allen, P. M. Lynch and J. M. Skibber, “Prognostic Implications of Response to Preoperative Infusional Chemoradiation in Locally Advanced Rectal Cancer,” Radiotherapy & Oncology, Vol. 51, No. 2, 1999, pp. 153-160. doi:10.1016/S0167-8140(99)00054-7

[17]   J. Dunst, T. Reese, T. Sutter, H. Zu¨hlke, A. Hinke, K. Ko¨lling-Schlebusch and S. Frings, “Phase I Trial Evaluating the Concurrent Combination of Radiotherapy and Capecitabine in Rectal Cancer,” Journal of Clinical Oncology, Vol. 20, No. 19, 2002,3983-3991. doi:10.1200/JCO.2002.02.049

[18]   J. Souglakos, N. Androulakis, D. Mavroudis, C. Kourousis, S. Kakolyris, N. Vardakis, K. Kalbakis, A. Pallis, A. Ardavanis, C. Varveris and V. Georgoulias, “Multicenter Dose-Finding Study of Concurrent Capecitabine and Radiotherapy as Adjuvant Treatment for Operable Rectal Cancer,” International Journal of Radiation Oncology, Biology, Physics, Vol. 56, No. 5, 2003, pp. 1284-1287. doi:10.1016/S0360-3016(03)00275-X

[19]   I. Craven, A. Crellin, R. Cooper, A. Melcher, P. Byrne and D. Sebag-Montefiore, “Preoperative Radiotherapy Combined with 5 Days Per Week Capecitabine Chemotherapy in Locally Advanced Rectal Cancer,” British Journal of Cancer, Vol. 97, No. 10, 2007, pp. 1333-1337. doi:10.1038/sj.bjc.6604042

[20]   C. Aschele, C. Pinto, S. Cordio, G. Rosati, A. Tagliagambe, S. Artale, P. Rosetti, S. Lonardi, L. Boni and L. Cionini, “Preoperative Fluorouracil (FU)-Based Chemoradiation with and Without Weekly Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Response Analysis of the Studio Terapia Adiuvante Reto (STAR)-01 Randomized Phase III Trial (Abstract #4008),” Journal of Clinical Oncology, Vol. 27, 2009, p. 804s.

[21]   J. Gerard, D. Azria, S. Gourgou-Bourgade, I. Martel-Laffay, C. Hennequin, P. L. Etienne, V. Vendrely, E. Francois, G. de La Roche, O. Bouche, X. Mirabel, B. Denis, L. Mineur, J. F. Berdah, M. A. Mahe, Y. Becouarn, O. Dupuis, G. Lledo, C. Montoto-Grillot and T. Conroy, “Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2,” Journal of Clinical Oncology, Vol. 28, No. 10, 2010, pp. 1638-1644. doi:10.1200/JCO.2009.25

[22]   T. Sato, H. Ozawa, K. Hatate, W. Onosato, M. Naito, T. Nakamura, A. Ihara, W. Koizumi, K. Hayakawa, I. Okayasu, K. Yamashita and M. Watanabe, “A Phase II Trial of Neoadjuvant Preoperative Chemoradiotherapy with S-1 plus Irinotecan and Radiation in Patients with Locally Advanced Rectal Cancer: Clinical Feasibility and Response Rate,” International Journal of Radiation Oncology, Biology, Physics, Vol. 79, No. 3, 2011, pp. 677-683. doi:10.1016/j.ijrobp.2009.11.007

[23]   B. Glimelius, U. Isacsson, B. Jung and L. Pahlman, “Radiotherapy in Addition to Radical Surgery in Rectal Cancer: Evidence for a Dose-Response Effect Favoring Preoperative Treatment,” International Journal of Radiation Oncology, Biology, Physics, Vol. 37, No. 2, 1997, pp. 281-287. doi:10.1016/S0360-3016(96)00510-X

[24]   K. L. Wiltshire, I. G. Ward, C. Swallow, C. S. Wong, R. Wong, L. L. Siu, M. Moore and J. Brierley, “Preoperative Radiation with Concurrent Chemotherapy for Resectable Rectal Cancer: Effect of Dose Escalation on Pathologic Complete Response, Local Recurrence-Free Survival, Disease-Free Survival, and Overall Survival,” International Journal of Radiation Oncology, Biology, Physics, Vol. 64, No. 3, 2006, pp. 709-716. doi:10.1016/j.ijrobp.2005.08.012

[25]   M. Mohiuddin, W. F. Regine, W. J. John, P. F. Hagihara, P. C. McGrath, D. E. Kenady and G. Marks, “Preoperative Chemoradiation in Fixed Distal Rectal Cancer: Dose Time Factors for Pathological Complete Response,” International Journal of Radiation Oncology, Biology, Physics, Vol. 46, No. 4, 2000, pp. 883-888. doi:10.1016/S0360-3016(99)00486-1

 
 
Top